Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
Mené sur 83 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de l'anlotinib au docétaxel après l'échec d'un traitement de première ligne à base de sels de platine
Objectives: Given the modest efficacy of docetaxel in advanced non-small cell lung cancer (NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in combination with docetaxel compared to docetaxel monotherapy as a second-line therapy for patients with advanced NSCLC. Materials and Methods: In this phase II study, patients with advanced NSCLC experiencing failure with first-line platinum-based regimens were randomized in a 1:1 ratio to receive either anlotinib plus docetaxel or docetaxel alone. Primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints. Results: A total of 83 patients were randomized. The combination of anlotinib and docetaxel significantly extended median PFS to 4.4 months compared to 1.6 months for docetaxel alone (hazard ratio [HR] = 0.38, 95 % confidence interval [CI]: 0.23–0.63, P = 0.0002), and also demonstrated superior ORR (32.5 % vs. 9.3 %, P = 0.0089) and DCR (87.5 % vs. 53.5 %, P = 0.0007). Median OS was observed at 12.0 months in the combination group versus 10.9 months in the monotherapy group (HR = 0.82, 95 % CI: 0.47–1.43, P = 0.4803). For patients previously treated with immunotherapy, the median PFS was notably longer at 7.8 versus 1.7 months (HR = 0.22, 95 % CI: 0.09–0.51, P = 0.0290). The incidence of grade
≥
3 treatment-related adverse events, predominantly leukopenia (15.0 % vs. 7.0 %) and neutropenia (10.0 % vs. 5.0 %), was manageable across both groups. Conclusion: Anlotinib plus docetaxel offers a viable therapeutic alternative for patients with advanced NSCLC who failed first-line platinum-based treatments.
Lung Cancer 2024